NEWS - Calypte Biomedical - 500 Beiträge pro Seite

[V51]

(PR NEWSWIRE) Calypte Launches Sales Initiative in Middle East
Calypte Launches Sales Initiative in Middle East

LAKE OSWEGO, Ore., Aug. 10 /PRNewswire-FirstCall/ -- Calypte Biomedical
Corporation (Amex: HIV), medical diagnostic tests manufacturer for the
professional point of care (PRO) and over the counter (OTC) segments of the
market primarily for the detection of antibodies to the human immunodeficiency
virus (HIV), announced today that it has received an order for 100,000 of its
over-the-counter (OTC) version of the Aware(TM) Oral Fluid HIV-1/2 Rapid
Diagnostic Test.
Joseph and Gionis, Calypte's exclusive distributor in the Middle East, is
initially focusing on the United Arab Emirates (UAE) with this order. The
value of this order is in excess of $250,000.
Dr. Gionis, President of Joseph and Gionis, commented, "Joseph and Gionis
has been actively involved with Calypte since the introduction of this
first-ever Over-the-Counter (OTC) HIV test at Arab Health, the largest
Healthcare Exhibition in the Middle East, held in Dubai last January. I am
pleased to see the progress we are now realizing. This first sizable order
will go into the UAE. At the same time, we are continuing to obtain regulatory
approvals throughout the region and expect to launch this OTC test into
additional countries in the coming months."
Dr. Gionis concluded, "While we are all saddened by the war in the Middle
East, HIV/AIDS continues to be a major focus and we expect to exceed our
one-year targets -- delivering at least 700,000 tests into a minimum of 7
countries in the region."
Roger I. Gale, Chairman and Chief Executive Officer of Calypte stated, "We
are starting to penetrate those markets where we have focused our initial
regulatory efforts, including South Africa and now the UAE. It is gratifying
to see the results and to be able to focus on the positive challenges of
ramping up our manufacturing efforts. I look forward to a having a growing and
productive relationship with Joseph and Gionis, as this organization continues
to utilize its expertise to facilitate the regulatory process in additional
countries within its territory. We will continue to keep you posted as we
expand our penetration into the Middle East."
About Joseph and Gionis:
Joseph and Gionis (www.josephandgionis.com ) is a global biotechnology
consulting and distribution firm with offices in Newport Beach, California and
the UAE, specializing in new scientific developments which contribute to
public health and welfare.
Joseph and Gionis is Calypte's exclusive distributor for 21 Middle Eastern
countries with a population of approximately 465 million people. According to
the December 2004 UNAIDS report, there are between 230,000 and 1.5 million
adults and children living with HIV within this region, of which nearly half
are women.
About Calypte Biomedical:
Calypte Biomedical Corporation (www.calypte.com ) is a U.S.-based
healthcare company focused on the development and commercialization of
diagnostic testing products for the detection of sexually transmitted diseases
such as the HIV-1 BED Incidence EIA and new diagnostic test products for the
rapid detection of HIV and other sexually transmitted diseases, several of
which do not require blood samples. Calypte believes there is a significant
need for rapid detection of such diseases globally to control their
proliferation, particularly in developing countries, which lack the medical
infrastructure to support laboratory-based testing. Calypte believes that
testing for HIV and other sexually transmitted infectious diseases may make
important contributions to public health, and could increase the likelihood of
treating those with undetected HIV and other sexually transmitted diseases.
Statements in this press release that are not historical facts are
forward-looking statements within the meaning of the Securities Act of 1933,
as amended. Those statements include statements regarding the intent, belief
or current expectations of the Company and its management. Such statements
reflect management's current views, are based on certain assumptions and
involve risks and uncertainties. Actual results, events, or performance may
differ materially from the above forward-looking statements due to a number of
important factors, and will be dependent upon a variety of factors, including,
but not limited to, the Company's ability to obtain additional financing, if
and as needed, and access funds from its existing financing arrangements that
will allow it to continue its current and future operations and whether demand
for its test products in domestic and international markets will generate
sufficient revenues to achieve positive cash flow and profitability. The
Company undertakes no obligation to publicly update these forward-looking
statements to reflect events or circumstances that occur after the date hereof
or to reflect any change in the Company's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events. Factors
that may impact the Company's success are more fully disclosed in the
Company's most recent public filings with the U.S. Securities and Exchange
Commission ("SEC"), including its annual report on Form 10-KSB for the year
ended December 31, 2005 and its subsequent filings with the SEC.
Company Contact: Investor Relations Contact:
Theodore R Gwin, Tim Clemensen,
Chief Financial Officer Rubenstein Investor Relations
[phone] Phone: [phone]
email: [e-mail] email: [e-mail]
SOURCE Calypte Biomedical Corporation


Contact Information:
Theodore R Gwin, Chief Financial Officer of Calypte Biomedical Corporation, +1-9
1-204-0282, [e-mail]; or Investor Relations, Tim Clemensen, +1-212-843-
337, [e-mail], of Rubenstein Investor Relations for Calypte B
omedical Corporation

WebSite:
http://www.josephandgionis.com
*** end of story ***

[mfierke]

das wird nichts mehr

[joelu]

Antwort auf Beitrag Nr.: 23.386.331 von mfierke am 10.08.06 15:39:11

mfierke, seit wann diese einsicht?

weiß roncalli das schon, dass das nichts mehr wird?